Drugs.com - Clinical Trials

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

CHICAGO, JUNE 1, 2025 – Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body’s immune system against...

Jun 3, 2025 - 05:35
 0
Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer
CHICAGO, JUNE 1, 2025 – Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body’s immune system against...
Read More

Tags:

Previous Article

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Sym...

Next Article

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of...

Related Posts

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas and Pfizer's Vepdegestrant Significantly Improv...

Jun 3, 2025  0

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics Achieves Primary Endpoint in Phase...

May 12, 2025  0

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

GLISTEN Phase III Trial Results Show Linerixibat Signif...

May 12, 2025  0